Heart Attack Test Delivers Results in One Hour
By LabMedica International staff writers Posted on 27 Aug 2012 |
A more sensitive blood test for heart attack may cut the diagnosis time to one hour, removing the need for prolonged monitoring of patients who present to the Emergency Department (ED).
The test, which screens more sensitively for changes in a standard biochemical marker for myocardial infarction or heart attack, may help move patients more quickly through the ED, thus reducing congestion and saving time and money.
Scientists at the University Hospital Basel (Switzerland) recruited 872 patients who presented to the ED with acute chest pain in a multicenter study. The cornerstone for diagnosing acute myocardial infarction (AMI) relies on clinical assessment, electrocardiography and measurement of a biochemical marker called cardiac troponin (or cTn). Without a rapid test for the marker, it can take three hours or more to check for increases in levels.
Blood samples for the determination of high-sensitivity cardiac troponin (hs-cTnT) were collected in serum tubes at presentation to the ED and additional samples were collected hourly thereafter. The samples were assayed in a blinded fashion using the Elecsys 2010 analyzer (Roche Diagnostics; Basel Switzerland). The team developed an algorithm for half of the patients and validated it in the remaining half. The algorithm used baseline hs-cTnT and absolute changes in levels of the biochemical marker within the first hour.
The final diagnosis of AMI was made in 147 (17%) of the patients. When they validated the test in the second group of patients, within one hour it classed 60% (259 patients) of them as rule-out, 17% (76) as rule-in, and 23% (101) as being in the observational zone. They found the cumulative 30-day survival was nearly 100%, 98.6% and 95.3% for patients classed as rule-out, observational zone, and rule-in respectively.
Tobias Reichlin, MD, the lead author of the study said, "Using a simple algorithm incorporating hs-cTnT baseline values and absolute changes within the first hour allowed a safe rule-out as well as an accurate rule-in of AMI within one hour in 77% of unselected patients with acute chest pain. This novel strategy may obviate the need for prolonged monitoring and serial blood sampling in three of four patients." The study was published on August 13, 2012, in the journal Archives of Internal Medicine.
Related Links:
University Hospital Basel
Roche Diagnostics
The test, which screens more sensitively for changes in a standard biochemical marker for myocardial infarction or heart attack, may help move patients more quickly through the ED, thus reducing congestion and saving time and money.
Scientists at the University Hospital Basel (Switzerland) recruited 872 patients who presented to the ED with acute chest pain in a multicenter study. The cornerstone for diagnosing acute myocardial infarction (AMI) relies on clinical assessment, electrocardiography and measurement of a biochemical marker called cardiac troponin (or cTn). Without a rapid test for the marker, it can take three hours or more to check for increases in levels.
Blood samples for the determination of high-sensitivity cardiac troponin (hs-cTnT) were collected in serum tubes at presentation to the ED and additional samples were collected hourly thereafter. The samples were assayed in a blinded fashion using the Elecsys 2010 analyzer (Roche Diagnostics; Basel Switzerland). The team developed an algorithm for half of the patients and validated it in the remaining half. The algorithm used baseline hs-cTnT and absolute changes in levels of the biochemical marker within the first hour.
The final diagnosis of AMI was made in 147 (17%) of the patients. When they validated the test in the second group of patients, within one hour it classed 60% (259 patients) of them as rule-out, 17% (76) as rule-in, and 23% (101) as being in the observational zone. They found the cumulative 30-day survival was nearly 100%, 98.6% and 95.3% for patients classed as rule-out, observational zone, and rule-in respectively.
Tobias Reichlin, MD, the lead author of the study said, "Using a simple algorithm incorporating hs-cTnT baseline values and absolute changes within the first hour allowed a safe rule-out as well as an accurate rule-in of AMI within one hour in 77% of unselected patients with acute chest pain. This novel strategy may obviate the need for prolonged monitoring and serial blood sampling in three of four patients." The study was published on August 13, 2012, in the journal Archives of Internal Medicine.
Related Links:
University Hospital Basel
Roche Diagnostics
Latest Clinical Chem. News
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Channels
Molecular Diagnostics
view channel
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Blood Test Could Identify Patients at Risk for Severe Scleroderma
Systemic sclerosis, also known as scleroderma, causes the hardening of the skin and connective tissues. In many cases, the disease can also damage vital organs, including the heart, kidneys, lungs, and... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more